NURG 5710 Pharm Exam with complete
solutions 2024/2025
ABSORPTION - ANSWER-the movement of a drug from it's site of administration
into the blood; influenced by cell membrane, blood flow at administration site,
drug solubility, molecular weight, drug concentration
VOLUME OF DISTRIBUTION - ANSWER-(Vd) a mathematically determined
measure of the size of a compartment that would be filled by the amount of a drug
in the same concentration found in the blood or plasma; useful in expressing
affinity of a drug to tissue and storage sites and in calculating a drug's clearance
from the body; larger volume of distribution indicates larger dose should be
administered to achieve a target concentration
METABOLISM - ANSWER-the process of chemically changing a drug to a
different compound called a metabolite; the enzymatic alteration of drug structure
to enhance excretion, inactivate, increase therapeutic action, activate a prodrug,
increase or decrease toxicity
PHASE I REACTION - ANSWER-chemical reactions seen in drug metabolism such
as oxidation, reduction, and hydrolysis
PHASE 2 REACTION - ANSWER-synthetic or conjugation reactions, involve the
attachment of another chemical group to a drug, resulting in a chemical with
greater water solubility needed for elimination
Schedule I drugs - ANSWER-have no accepted medical or legal use and are for
research facilities only (heroin, LSD).
, Schedule II drugs - ANSWER-can't be filled by refill nor by telephone order
(unless emergent with written prescription in seven days).
E-scribe allowed with specified software and secure identification (morphine,
codeine, mereperidine, opium, cocaine, amphetamine, phenobarbital,
secobarbital).
Schedule III drugs - ANSWER-must have prescription rewritten after six months
and may be telephoned or faxed (codeine combined with non-narcotics,
hydrocodone, benzphetamine, chlorpheniramine, butabarbital)
Schedule IV drugs - ANSWER-like schedule III drugs in that prescriptions must be
rewritten after six months and may be telephoned or faxed in, however, illegal
possession are different (pentazocine, propoxyphene, phentermine,
benzodiazepines).
Schedule V controls - ANSWER-same as all prescription drugs if regulated by the
state; these may be OTC (loperamide, diphenoxylate).
Type A adverse reactions - ANSWER-are dose dependent, common, and are
related to the pharmacological effects of a drug. These are predictable and
common
Type B adverse reactions - ANSWER-are allergic or idiosyncratic, not dose
dependent, unpredictable, and unpreventable. They are not related to the
pharmacological action of the drug.
Type C adverse reactions - ANSWER-are fairly uncommon and are related to
cumulative dosing of a drug (dose and time related).
Type D adverse reactions - ANSWER-are delayed reactions, are time related, and
are uncommon. They are apparent after the use of a drug.
Type E adverse reactions - ANSWER-are withdrawal reactions and can be
predictable or unpredictable.
Type F adverse reactions - ANSWER-are unexpected failure of the drug therapy,
often due to drug interactions, and are common.
For which patients would you avoid prescribing systemic decongestants? -
ANSWER-Persons with hypertension, insomnia, rhythm disturbances, heart
failure, BPH, and glaucoma should have cautious use of systemic decongestants
solutions 2024/2025
ABSORPTION - ANSWER-the movement of a drug from it's site of administration
into the blood; influenced by cell membrane, blood flow at administration site,
drug solubility, molecular weight, drug concentration
VOLUME OF DISTRIBUTION - ANSWER-(Vd) a mathematically determined
measure of the size of a compartment that would be filled by the amount of a drug
in the same concentration found in the blood or plasma; useful in expressing
affinity of a drug to tissue and storage sites and in calculating a drug's clearance
from the body; larger volume of distribution indicates larger dose should be
administered to achieve a target concentration
METABOLISM - ANSWER-the process of chemically changing a drug to a
different compound called a metabolite; the enzymatic alteration of drug structure
to enhance excretion, inactivate, increase therapeutic action, activate a prodrug,
increase or decrease toxicity
PHASE I REACTION - ANSWER-chemical reactions seen in drug metabolism such
as oxidation, reduction, and hydrolysis
PHASE 2 REACTION - ANSWER-synthetic or conjugation reactions, involve the
attachment of another chemical group to a drug, resulting in a chemical with
greater water solubility needed for elimination
Schedule I drugs - ANSWER-have no accepted medical or legal use and are for
research facilities only (heroin, LSD).
, Schedule II drugs - ANSWER-can't be filled by refill nor by telephone order
(unless emergent with written prescription in seven days).
E-scribe allowed with specified software and secure identification (morphine,
codeine, mereperidine, opium, cocaine, amphetamine, phenobarbital,
secobarbital).
Schedule III drugs - ANSWER-must have prescription rewritten after six months
and may be telephoned or faxed (codeine combined with non-narcotics,
hydrocodone, benzphetamine, chlorpheniramine, butabarbital)
Schedule IV drugs - ANSWER-like schedule III drugs in that prescriptions must be
rewritten after six months and may be telephoned or faxed in, however, illegal
possession are different (pentazocine, propoxyphene, phentermine,
benzodiazepines).
Schedule V controls - ANSWER-same as all prescription drugs if regulated by the
state; these may be OTC (loperamide, diphenoxylate).
Type A adverse reactions - ANSWER-are dose dependent, common, and are
related to the pharmacological effects of a drug. These are predictable and
common
Type B adverse reactions - ANSWER-are allergic or idiosyncratic, not dose
dependent, unpredictable, and unpreventable. They are not related to the
pharmacological action of the drug.
Type C adverse reactions - ANSWER-are fairly uncommon and are related to
cumulative dosing of a drug (dose and time related).
Type D adverse reactions - ANSWER-are delayed reactions, are time related, and
are uncommon. They are apparent after the use of a drug.
Type E adverse reactions - ANSWER-are withdrawal reactions and can be
predictable or unpredictable.
Type F adverse reactions - ANSWER-are unexpected failure of the drug therapy,
often due to drug interactions, and are common.
For which patients would you avoid prescribing systemic decongestants? -
ANSWER-Persons with hypertension, insomnia, rhythm disturbances, heart
failure, BPH, and glaucoma should have cautious use of systemic decongestants
